Authors: Vickers, TA Wyatt, JR Burckin, T Bennett, CF Freier, SM

Citation: Ta. Vickers et al., Fully modified 2 ' MOE oligonucleotides redirect polyadenylation, NUCL ACID R, 29(6), 2001, pp. 1293-1299

Authors: Geary, RS Khatsenko, O Bunker, K Crooke, R Moore, M Burckin, T Truong, L Sasmor, H Levin, AA

Citation: Rs. Geary et al., Absolute bioavailability of 2 '-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats, J PHARM EXP, 296(3), 2001, pp. 898-904

Authors: Yu, RZ Geary, RS Leeds, JM Watanabe, T Moore, M Fitchett, J Matson, J Burckin, T Templin, MV Levin, AA

Citation: Rz. Yu et al., Comparison of pharmacokinetics and tissue disposition of an antisense phosphorothioate oligonucleotide targeting human Ha-ras mRNA in mouse and monkey, J PHARM SCI, 90(2), 2001, pp. 182-193

Authors: Leeds, JM Henry, SP Geary, R Burckin, T Levin, AA

Citation: Jm. Leeds et al., Comparison of the pharmacokinetics of subcutaneous and intravenous administration of a phosphorothioate oligodeoxynucleotide in cynomolgus monkeys, ANTISENSE N, 10(6), 2000, pp. 435-441

Authors: Monteith, DK Horner, MJ Gillett, NA Butler, M Geary, R Burckin, T Ushiro-Watanabe, T Levin, AA

Citation: Dk. Monteith et al., Evaluation of the renal effects of an antisense phosphorothioate oligodeoxynucleotide in monkeys, TOX PATHOL, 27(3), 1999, pp. 307-317